. Author manuscript; available in PMC: 2022 Apr 15.

Published in final edited form as: Lancet Haematol. 2019 May 3;6(6):e317–e327. doi: 10.1016/S2352-3026(19)30029-8

Table 3:

Transfusion independence

	Guadecitabine dose		Disease cohort		All patients
	60 mg/m²	90 mg/m²	Treatment-naive	Relapsed or refractory
Baseline RBC dependence	31	27	24	34	58

RBC independence for 8 weeks	7 (23%)	8 (30%)	10 (42%)	5 (15%)	15 (26%)

RBC independence for 16 weeks	5 (16%)	4 (15%)	6 (25%)	3 (9%)	9 (16%)

Baseline platelet dependence	13	15	12	16	28

Platelet independence for 8 weeks	3 (23%)	8 (53%)	6 (50%)	5 (31%)	11 (39%)

Platelet independence for 16 weeks	2 (15%)	4 (27%)	4 (33%)	2 (13%)	6 (21%)

Data are n or n (%) of patients with baseline dependence.

RBC=red blood cell.